KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Retained Earnings (2016 - 2025)

Cvs Health (CVS) has disclosed Retained Earnings for 17 consecutive years, with $406.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 438.33% year-over-year to $406.0 million, compared with a TTM value of $406.0 million through Dec 2025, up 438.33%, and an annual FY2025 reading of $406.0 million, up 438.33% over the prior year.
  • Retained Earnings was $406.0 million for Q4 2025 at Cvs Health, down from $59.1 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $63.9 billion in Q2 2025 and bottomed at -$1.6 billion in Q3 2022.
  • Average Retained Earnings over 5 years is $23.7 billion, with a median of $993.5 million recorded in 2021.
  • The sharpest move saw Retained Earnings tumbled 184.44% in 2022, then soared 28180.86% in 2025.
  • Year by year, Retained Earnings stood at $965.0 million in 2021, then skyrocketed by 5744.35% to $56.4 billion in 2022, then rose by 9.23% to $61.6 billion in 2023, then crashed by 100.19% to -$120.0 million in 2024, then soared by 438.33% to $406.0 million in 2025.
  • Business Quant data shows Retained Earnings for CVS at $406.0 million in Q4 2025, $59.1 billion in Q3 2025, and $63.9 billion in Q2 2025.